NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 807-815

  Furuhashi, Satoshi ^a   Sugita, Hiroki ^a,b   Takamori, Hiroshi ^a   Horino, Kei ^a   Nakahara, Osamu ^a   Okabe, Hirohisa ^a   Miyake, Keisuke ^a   Tanaka, Hiroshi ^a   Beppu, Toru ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto City Municipal Hospital   (Japan)

Author keywords

Akt; Cancer invasion; Cancer proliferation; Colon cancer; Epidermal growth factor receptor; Extracellular signal regulated kinase; Insulin like growth factor receptor; MEK; Nitric oxide; Pancreatic cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE DONOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S NITROSOGLUTATHIONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; HCT116 CELLS; HT29 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRILES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; S-NITROSOGLUTATHIONE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84857174690     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1243     Document Type: Article

References (48)

1. Bergmann U, Funatomi H, Yokoyama M, Beger HG and Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55: 2007-2011, 1995.
2. Furukawa M, Raffeld M, Mateo C, et al: Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 11: 3233-3242, 2005. (Pubitemid 40627870)
3. Kim HJ, Litzenburger BC, Cui X, et al: Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 27: 3165-3175, 2007. (Pubitemid 46581327)
4. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
5. Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21, 2003. (Pubitemid 36457237)
6. Ito T, Sasaki Y and Wands JR: Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. Mol Cell Biol 16: 943-951, 1996. (Pubitemid 26061665)
7. Tanaka S and Wands JR: A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 98: 2100-2108, 1996. (Pubitemid 26376299)
8. Park HS, Huh SH, Kim MS, Lee SH and Choi EJ: Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. Proc Natl Acad Sci USA 97: 14382-14387, 2000. (Pubitemid 32016584)
9. Reynaert NL, Ckless K, Korn SH, et al: Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci USA 101: 8945-8950, 2004. (Pubitemid 38781591)
10. Mannick JB, Hausladen A, Liu L, et al: Fas-induced caspase denitrosylation. Science 284: 651-654, 1999. (Pubitemid 29289591)
11. Yasukawa T, Tokunaga E, Ota H, Sugita H, Martyn JA and Kaneki M: S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem 280: 7511-7518, 2005. (Pubitemid 40349643)
12. Ambs S, Merriam WG, Ogunfusika MO, et al: p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 4: 1371-1376, 1998. (Pubitemid 28553458)
13. Camp ER, Yang A, Liu W, et al: Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12: 2628-2633, 2006.
14. Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H and Baba H: Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res 8: 1152-1163, 2010.
15. Kalivendi SV, Kotamraju S, Zhao H, Joseph J and Kalyanaraman B: Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem 276: 47266-47276, 2001.
16. Wang B, Wei D, Crum VE, et al: A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 22: 1771-1782, 2003. (Pubitemid 36513137)
17. Peshes-Yaloz N, Rosen D, Sondel PM, Krammer PH and Berke G: Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology 120: 502-511, 2007. (Pubitemid 46365008)
18. Kotamraju S, Williams CL and Kalyanaraman B: Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 67: 7386-7394, 2007. (Pubitemid 47206569)
19. Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E and Castanas E: Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta 1760: 1657-1666, 2006. (Pubitemid 44667277)
20. Jarry A, Charrier L, Bou-Hanna C, et al: Position in cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death. Cancer Res 64: 4227-4234, 2004. (Pubitemid 38802427)
21. Chawla-Sarkar M, Bauer JA, Lupica JA, et al: Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 278: 39461-39469, 2003. (Pubitemid 37248502)
22. Lim KH, Ancrile BB, Kashatus DF and Counter CM: Tumour maintenance is mediated by eNOS. Nature 452: 646-649, 2008. (Pubitemid 351483359)
23. Shields JM, Pruitt K, McFall A, Shaub A and Der CJ: Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10: 147-154, 2000. (Pubitemid 30171309)
24. Van der Heyden MA, van Bergen en Henegouwen PM, De Ruiter N, et al: The actin binding domain of the epidermal growth factor receptor is required for EGF-stimulated tissue invasion. Exp Cell Res 234: 521-526, 1997.
25. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005. (Pubitemid 47050835)
26. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356, 2008.
27. Wee S, Jagani Z, Xiang KX, et al: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293, 2009.
28. Yu K, Toral-Barza L, Shi C, Zhang WG and Zask A: Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7: 307-315, 2008.
29. Murillo-Carretero M, Torroglosa A, Castro C, Villalobo A and Estrada C: S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity. Free Radic Biol Med 46: 471-479, 2009.
30. Studer RK: Nitric oxide decreases IGF-1 receptor function in vitro; glutathione depletion enhances this effect in vivo. Osteoarthritis Cartilage 12: 863-869, 2004.
31. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 14: 3651-3656, 2008.
32. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554, 1988.
33. Bos JL, Fearon ER, Hamilton SR, et al: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987. (Pubitemid 17075079)
34. Bocci G, Fioravanti A, Orlandi P, et al: Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93: 319-330, 2005. (Pubitemid 43080034)
35. Allgayer H, Wang H, Shirasawa S, Sasazuki T and Boyd D: Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer 80: 1884-1891, 1999. (Pubitemid 29391270)
36. Favata MF, Horiuchi KY, Manos EJ, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998. (Pubitemid 28334795)
37. Liu D, Liu Z, Jiang D, Dackiw AP and Xing M: Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 92: 4686-4695, 2007. (Pubitemid 350223445)
38. Henderson YC, Fredrick MJ and Clayman GL: Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Arch Otolaryngol Head Neck Surg 133: 810-815, 2007. (Pubitemid 47295764)
39. Henderson YC, Ahn SH and Clayman GL: Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. Arch Otolaryngol Head Neck Surg 135: 347-354, 2009.
40. Haura EB, Ricart AD, Larson TG, et al: A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16: 2450-2457, 2010.
41. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16: 1924-1937, 2010.
42. Ibiza S, Perez-Rodriguez A, Ortega A, et al: Endothelial nitric oxide synthase regulates N-Ras activation on the Golgi complex of antigen-stimulated T cells. Proc Natl Acad Sci USA 105: 10507-10512, 2008.
43. Yu CF, Liu ZX and Cantley LG: ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J Biol Chem 277: 19382-19388, 2002. (Pubitemid 34967445)
44. Yoon YK, Kim HP, Han SW, et al: Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 8: 2526-2536, 2009.
45. Adams C, McCarthy HO, Coulter JA, et al: Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med 11: 160-168, 2009.
46. Kiziltepe T, Hideshima T, Ishitsuka K, et al: JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110: 709-718, 2007. (Pubitemid 47105410)
47. Wang Z, Cook T, Alber S, et al: Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 64: 1386-1395, 2004. (Pubitemid 38235607)
48. Ma Q, Wang Y, Gao X, Ma Z and Song Z: L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res 13: 7407-7412, 2007.